Pharmacologist, calls for a guideline for standard quality for drugs to be formulated.

Hyderabad: The Central Drugs Laboratory and Regional Drugs Testing Laboratory are not carrying out checks to see if drugs are of standard quality (SQ) and labelling them as such. Government hospitals too do not carry out tests on sample batches of medicines supplied to them. This results in substandard drugs often being used. Dr Naveen Kumar, a senior pharmacologist, calls for a guideline for standard quality for drugs to be formulated. “This will then allow categorisation of drugs. Due to constant complaints of low quality of drugs, and the slow pace of growth of generic medicines in India, a pressure group is demanding that there must be data on standard quality drugs,” he says.

Generic drugs exported to European countries and the US have proper labelling and are constantly checked by the Food and Drug Administration, so the demand for a similar process to be set up in India is eminently reasonable. The Drugs Controller General of India has made several representations for guidelines and data of SQ drugs manufactured in India. But no data has been published by the government so far.

A senior drug control officer in TS explained, “Presently, 80 per cent of anti-retro viral drugs used worldwide to combat AIDS are from Indian pharmaceutical companies. The quality and efficacy of drugs manufactured by domestic players has helped to carve a niche in the global generic market. The problems being seen in India are from manufacturers who are not in the branded generic category. These players need to be regulated and till that is done, the issue of efficacy will be raised from time to time.”

To carry out tabulation of standard quality, the Drug Controller of India has to have sufficient manpower for checking, testing and regulating. With huge volumes being produced and the unorganized sector being involved, it is a challenge. The organised sector gets visits from inspectors from time to time, and sudden inspections are carried out only on suspicion. The SQ data will create clarity for the pharmaceutical companies and also the governing body, and benefit patients and hence there is increasing pressure that it must be formulated.

Related Posts

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore